D
Dawn Waterworth
Researcher at GlaxoSmithKline
Publications - 19
Citations - 2524
Dawn Waterworth is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Polycystic ovary & Genome-wide association study. The author has an hindex of 14, co-authored 19 publications receiving 2294 citations. Previous affiliations of Dawn Waterworth include Imperial College London.
Papers
More filters
Journal ArticleDOI
Genetics of polycystic ovary syndrome
Stephen Franks,Neda Gharani,Dawn Waterworth,Sari Batty,Davinia White,Robert Williamson,Mark I. McCarthy +6 more
TL;DR: Evidence is found that CYP11a (coding for P450 cholesterol side chain cleavage) and the insulin VNTR regulatory polymorphism are important genes in the aetiology of PCOS and may explain, in part, the heterogeneity of the syndrome.
Journal ArticleDOI
Integrated Functional Genomic Analysis Enables Annotation of Kidney Genome-Wide Association Study Loci.
Karsten B. Sieber,Anna Batorsky,Kyle Siebenthall,Kelly L. Hudkins,Jeff Vierstra,Shawn Sullivan,Aakash Sur,Michelle McNulty,Richard Sandstrom,Alex Reynolds,Daniel Bates,Morgan Diegel,Douglass Dunn,J. K. Nelson,Michael Buckley,Rajinder Kaul,Matthew G. Sampson,Jonathan Himmelfarb,Charles E. Alpers,Dawn Waterworth,Shreeram Akilesh +20 more
TL;DR: A powerful approach is demonstrated to functionally connect kidney disease-/trait-associated loci to their target genes by leveraging unique regulatory DNA maps and integrated epigenomic and genetic analysis and will enhance the understanding of genome regulation and its effects on gene expression in kidney disease.
Journal ArticleDOI
Assessment of rosacea symptom severity by genome-wide association study and expression analysis highlights immuno-inflammatory and skin pigmentation genes.
Jennifer L. Aponte,Mathias Chiano,Laura M. Yerges-Armstrong,David A. Hinds,Chao Tian,Akanksha Gupta,Cong Guo,Dana Fraser,Johannes M. Freudenberg,Deepak K. Rajpal,Margaret G. Ehm,Dawn Waterworth +11 more
TL;DR: The identified loci provide specificity of inflammatory mechanisms in rosacea, and identify potential pathways for therapeutic intervention.
Journal ArticleDOI
Lipoprotein-Associated Phospholipase A2 Loss-of-Function Variant and Risk of Vascular Diseases in 90,000 Chinese Adults.
Iona Y. Millwood,Derrick A Bennett,Robin G. Walters,Robert Clarke,Dawn Waterworth,Toby Johnson,Yiping Chen,Ling Yang,Yu Guo,Zheng Bian,Alex Hacker,Astrid Yeo,Sarah Parish,Michael Hill,Stephanie L. Chissoe,Richard Peto,Lon R. Cardon,Rory Collins,Liming Li,Zhengming Chen +19 more
TL;DR: Recent phase III trials of the Lp-PLA2 inhibitor darapladib failed to establish a protective role of dara pladib for prevention of major vascular events in patients with stable coronary heart disease (CHD) or acute coronary syndrome 1, 2.
Journal ArticleDOI
Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study.
Lauren E. Mokry,Lauren E. Mokry,Sirui Zhou,Cong Guo,Robert A. Scott,Robert A. Scott,Luke Devey,Claudia Langenberg,Nicholas J. Wareham,Dawn Waterworth,Lon R. Cardon,Philippe Sanseau,George Davey Smith,J. Brent Richards +13 more
TL;DR: Genomic findings implicated IBD as an alternative indication for anti-IL18 therapy, which should be tested in randomized controlled trials.